Antiangiogenic drugs for treatment of vascular malformations and angiodysplasia-related gastrointestinal bleeding;Angiogeneseinhibitoren zur behandlung angiodysplasie-assoziierter gastrointestinaler blutungen

Deutsche Medizinische Wochenschrift

Volumn 134, Issue 38, 2009, Pages 1893-1896

  Bauditz, J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Angiodysplasias; Angiogenesis; Gastrointestinal bleeding; Oslers disease; Thalidomide

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BEVACIZUMAB; ENDOSTATIN; KRN 951; LENALIDOMIDE; POMALIDOMIDE; RANIBIZUMAB; SEMAXANIB; SORAFENIB; SUNITINIB; THALIDOMIDE; VASCULOTROPIN; VATALANIB; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ANGIODYSPLASIA; ANGIOGENESIS; ATAXIA; BREAST CANCER; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONSTIPATION; CROHN DISEASE; DIARRHEA; DRUG MECHANISM; DYSPNEA; ENTEROPATHY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TUMOR; GENE MUTATION; HAND FOOT SYNDROME; HEMANGIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CARCINOMA; MULTIPLE MYELOMA; MUSCLE HYPERTONIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PROTEIN EXPRESSION; PROTEINURIA; RENDU OSLER WEBER DISEASE; REVIEW; SEDATION; SIDE EFFECT; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT; VON HIPPEL LINDAU DISEASE; ANIMAL; CAPILLARY; GASTROINTESTINAL TRACT; GENETICS; INTESTINE MUCOSA; PATHOLOGY; VASCULARIZATION;

ANGIODYSPLASIA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CAPILLARIES; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TRACT; HUMANS; INTESTINAL MUCOSA; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; THALIDOMIDE;

EID: 70349333710     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0029-1237529     Document Type: Review

References (16)

1. Amato de RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-4085
2. Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohns disease. Gut 2002; 50: 196-200
3. Bauditz J, Schachschal G, Wedel S, Lochs H. Thalidomide for treatment of severe intestinal bleeding. Gut 2004; 53: 609-613
4. Bauditz J, Lochs H, Voderholzer W. Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide. Endoscopy 2006; 38: 1036-1039
5. Cirulli A, Liso A, DOvidio F et al. Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia. Acta Haematol 2003; 110: 29-32
6. Junquera F, Feu F, Papo M et al. A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterology 2001; 121: 1073-1079
7. Junquera F, Saperas E, de Torres I, Vidal MT, Malagelada JR. Increased expression of angiogenic factors in human colonic angiodysplasia. Am J Gastroenterol 1999; 94: 1070-1076
8. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65
9. Kurstin R. Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease. Oncology 2002; 16: 21-24
10. Madhusudan S, Deplanque G, Braybrooke JP et al. Antiangiogenic therapy for von Hippel-Lindau disease. JAMA 2004; 291: 943-944
11. Nardone G, Rocco A, Balzano T, Budillon G. The efficacy of octreotide therapy in chronic bleeding due to vascular abnormalities of the gastrointestinal tract. Aliment Pharmacol Ther 1999; 13: 1429-1436
12. Perez-Encinas M, Rabunal Martinez MJ, Bello Lopez JL. Is thalidomide effective for the treatment of gastrointestinal bleeding in hereditary hemorrhagic telangiectasia? Haematologica 2002; 87: 34-35
13. SScaglione G, Pietrini L, Russo F et al. Long-acting octreotide as rescue therapy in chronic bleeding from gastrointestinal angiodysplasia. Aliment Pharmacol Ther 2007; 26: 935-942
14. Shurafa M, Kamboj G. Thalidomide for the treatment of bleeding angiodysplasias. Am J Gastroenterol 2003; 98: 221-222
15. van Heeckeren WJ, Sanborn SL, Narayan A et al. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis. Curr Opin Hematol 2007; 14: 468-480
16. Vase P. Estrogen treatment of hereditary hemorrhagic telangiectasia. A double-blind controlled clinical trial. Acta Med Scand 1981; 209: 393-396